Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | Novel therapies for high-risk MDS

Sangmin Lee • 4 Jun 2021
EHA 2021
Myelodysplastic Syndromes Antibodies Azacitidine Magrolimab Sabatolimab Venetoclax

Sangmin Lee, MD, Weill Cornell Medicine, New York City, NY, gives an overview of novel therapies for the treatment of high-risk myelodysplastic syndromes (MDS). Dr Lee comments on the need for therapies for patients who are relapsed/refractory to hypomethylating agents (HMAs), and highlights novel therapies such as sabatolimab, a TIM-3 inhibitor which is currently being investigated in a Phase II trial. Dr Lee also talks on the potential benefits of magrolimab and venetoclax, which are being investigated in combination with azacitidine. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

More from Sangmin Lee

1:45
Updates on the treatment of MDS
Sangmin Lee • 20 Oct 2021
1:07
Challenges in treating AML
Sangmin Lee • 20 Oct 2021
1:13
Rare blood diseases at LLM 2021
Sangmin Lee • 20 Oct 2021
2:10
Updated overall survival data on eltanexor for HMA-refractory MDS
Sangmin Lee • 4 Jun 2021

Related Videos

2:22
Haplo-SCT for older patients with AML/MDS, and should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals